Versapeutics Inc.
San Diego, CA Versapeutics,Inc.
- UEI
- EGSGJKXHKBN5
- CAGE
- 80VT7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 6525 Caminito Stella, San Diego, CA 92130, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Toxicology and efficacy studies of intrathecal versamab-101 for spinal cord injury treatment - project… | National Institute of Neurological Disorders and Stroke | $2,380,552 | |
| Developing therapeutic antibodies for alzheimer's disease - project summary/abstract millions of americans suffer from… | National Institute on Aging | $979,256 | |
| Developing therapeutic antibodies for alzheimer's disease - project summary/abstract millions of americans suffer from… | National Institute on Aging | $997,068 | |
| Preclinical toxicology study of intrathecal versamab-101 for spinal cord injury treatment - project summary/abstract… | National Institute of Neurological Disorders and Stroke | $4,315,987 | |
| Pharmacokinetics and efficacy of intrathecal versamab-101 delivery foracute spinal cord injury - project… | National Institute of Neurological Disorders and Stroke | $990,274 |
About Versapeutics Inc.
Versapeutics Inc. is a for-profit biotechnology company developing novel therapeutics, including monoclonal antibodies, to treat diseases of the central nervous system such as spinal cord injury, Alzheimer's disease, and other neurodegenerative disorders. Through federal grants from the National Institutes of Health, the company conducts preclinical research and development activities to advance its therapeutic candidates towards clinical trials and potential commercialization.
Specifically, Versapeutics has received funding to support pharmacokinetic, toxicology, and efficacy studies in animal models for its lead clinical candidate Versamab-101, an antibody designed to promote axon regeneration and functional recovery after acute spinal cord injury. Additional NIH grants back preclinical development of Versapeutics' Alzheimer's disease compounds and next-generation spinal cord injury therapies. Across awards, the company provides antibody engineering, cell-based assay development, animal model testing services, and preclinical trial design and coordination. Major funding agencies include National Institute of Neurological Disorders and Stroke through the Extramural Research Programs in the Neurosciences and Neurological Disorders, and National Institute on Aging through the Aging Research program. Partners have included academic research groups such as those at the University of California, San Diego.
Quick answers
What is Versapeutics Inc.'s UEI?
Versapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is EGSGJKXHKBN5.
What is Versapeutics Inc.'s CAGE code?
Versapeutics Inc.'s CAGE code is 80VT7.
What is Versapeutics Inc.'s primary NAICS code?
Versapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Versapeutics Inc. located?
Versapeutics Inc.'s physical address in SAM.gov is 6525 Caminito Stella, San Diego, CA 92130, USA.
Is Versapeutics Inc. registered in SAM.gov?
Yes. Versapeutics Inc.'s SAM.gov registration is active through March 10, 2027.
What is Versapeutics Inc.'s most recent federal award?
Versapeutics Inc.'s most recent federal grant award is Toxicology and efficacy studies of intrathecal versamab-101 for spinal cord injury treatment - project… (R44NS120397), from National Institute of Neurological Disorders and Stroke, on September 18, 2023.
On GovTribe
See Versapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors